Trial Profile
A Phase IIb Multicenter, Randomized, Double-blind Study of ALX-0061 Administered Subcutaneously as Monotherapy, in Subjects With Moderate to Severe Rheumatoid Arthritis Who Are Intolerant to Methotrexate or for Whom Continued Methotrexate Treatment is Inappropriate
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Mar 2023
Price :
$35
*
At a glance
- Drugs Vobarilizumab (Primary) ; Tocilizumab
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Ablynx
- 08 Nov 2017 Results of this and ALX0061-C201 trials assessing efficacy and safety, presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
- 17 Jun 2017 Results assessing the safety and efficacy of Vobarilizumab in patients with moderate to severe rheumatoid arthritis, presented at the 18th Annual Congress of the European League Against Rheumatism.
- 14 Jun 2017 According to an Ablynx media release, results from this trial will be presented at the European Congress of Rheumatology (EULAR).